Hutchmed (HCM) announced that its partner Takeda (TAK) has received approval from the Japanese Ministry of Health, Labour and Welfare, or MHLW, to manufacture and market Fruzaqla for previously treated metastatic colorectal cancer, or CRC. Fruzaqla is the first novel targeted therapy in Japan to be approved for metastatic CRC, regardless of biomarker status, in over a decade. Fruzaqla has been approved for the treatment of advanced or recurrent CRC that is neither curable nor resectable and that has progressed after chemotherapy.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HCM:
- HUTCHMED Announces Japan Approval for FRUZAQLA® (fruquintinib) Received by Takeda
- HUTCHMED Highlights Clinical Data to be Presented at ESMO Congress 2024 and the 2024 World Conference of Lung Cancer
- Hutchmed withdraws NDA in China for fruquintinib in combination with paclitaxel
- HUTCHMED Provides Update on Fruquintinib for Second-Line Gastric Cancer in China
- HUTCHMED to Host Expert Call to discuss Immune Thrombocytopenia